Sionna Therapeutics (NASDAQ:SION) Director Ra Capital Management, L.P. Sells 47,442 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Ra Capital Management, L.P. sold 47,442 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $40.01, for a total value of $1,898,154.42. Following the sale, the director directly owned 168,193 shares of the company’s stock, valued at $6,729,401.93. This represents a 22.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Tuesday, November 18th, Ra Capital Management, L.P. sold 6,922 shares of Sionna Therapeutics stock. The shares were sold at an average price of $39.57, for a total value of $273,903.54.
• On Monday, November 17th, Ra Capital Management, L.P. sold 81,987 shares of Sionna Therapeutics stock. The shares were sold at an average price of $40.59, for a total value of $3,327,852.33.
• On Tuesday, October 28th, Ra Capital Management, L.P. sold 62,610 shares of Sionna Therapeutics stock. The stock was sold at an average price of $39.58, for a total value of $2,478,103.80.
• On Friday, October 24th, Ra Capital Management, L.P. sold 311,000 shares of Sionna Therapeutics stock. The shares were sold at an average price of $39.50, for a total value of $12,284,500.00.

Sionna Therapeutics Stock Performance

SION traded down $0.71 during mid-day trading on Wednesday, reaching $38.41. 255,628 shares of the stock were exchanged, compared to its average volume of 239,955. Sionna Therapeutics, Inc. has a 1 year low of $7.26 and a 1 year high of $43.19. The stock has a market capitalization of $1.71 billion and a PE ratio of -7.89. The company has a 50 day moving average price of $32.03 and a two-hundred day moving average price of $22.90.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Siren L.L.C. bought a new position in shares of Sionna Therapeutics during the 1st quarter worth $3,400,000. Zimmer Partners LP purchased a new stake in Sionna Therapeutics during the first quarter valued at about $2,484,000. Goldman Sachs Group Inc. bought a new position in Sionna Therapeutics during the first quarter worth about $667,000. Alyeska Investment Group L.P. purchased a new position in shares of Sionna Therapeutics in the first quarter worth about $1,948,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Sionna Therapeutics in the first quarter worth about $676,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on SION shares. BTIG Research initiated coverage on Sionna Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $50.00 target price on the stock. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price target for the company. Wall Street Zen cut Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Thursday, November 13th. Finally, Jones Trading started coverage on Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.